Skip to main content
Premium Trial:

Request an Annual Quote

RXi Regains Nasdaq Listing

Premium

RXi Pharmaceuticals announced this month that its stock has once again begun trading on the Nasdaq stock market.

"Listing on Nasdaq will help us gain access to a broader institutional investment community and to provide greater liquidity for our shareholders," RXi President and CEO Geert Cauwenbergh said in a statement.

RXi had previously traded on the Nasdaq but lost its listing when it merged with Apthera in 2011. The new company changed its name to Galena, took RXi’s stock listing, and made RXi a subsidiary. RXi was later spun out as a publicly traded independent company again, but traded on the over-the-counter bulletin board.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.